Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508337 | 0.81 | POLL (0.43) | KMT2APOLLOPRL1KCNH2S1PR1 | |
| SCHEMBL17571276 | 0.81 | POLL (0.43) | KMT2APOLLOPRL1KCNH2S1PR1 | |
| SCHEMBL1508764 | 0.81 | POLL (0.43) | KMT2APOLLOPRL1KCNH2S1PR1 | |
| SCHEMBL9456077 | 0.79 | HTR2A (0.43) | KMT2APOLLOPRL1KCNH2HTR2A | |
| SCHEMBL9455939 | 0.76 | KMT2A (0.37) | KMT2APOLLOPRL1KCNH2S1PR1 | |
| SCHEMBL17563590 | 0.75 | CA2 (0.41) | KMT2APOLLOPRL1KCNH2S1PR1 | |
| SCHEMBL17563589 | 0.75 | CA2 (0.41) | KMT2APOLLOPRL1KCNH2S1PR1 | |
| SCHEMBL9455921 | 0.74 | GABRA1 (0.42) | KMT2APOLLADRA1A | |
| SCHEMBL9506611 | 0.74 | TBXA2R (0.42) | KMT2APOLLADRA1A | |
| SCHEMBL28950294 | 0.74 | KMT2A (0.38) | KMT2APOLLOPRL1KCNH2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646425-B1 | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome | BOEHRINGER INGELHEIM INT (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2646425-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | Boehringer Ingelheim International GmbH (DE) | 2013-10-09 | — | — | EP | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012072691-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302566-A1 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, INSR, GPR52 | RIPK1 3968/4885KMT2A 3811/4885POLL 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.